ArticleJournal of applied physiology (Bethesda, Md. : 1985)2014
Mature IGF-I excels in promoting functional muscle recovery from disuse atrophy compared with pro-IGF-IA.
Article in Journal of applied physiology (Bethesda, Md. : 1985), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Regenerative Medicine: Advanced Therapy for Muscle Tissue Restoration.International journal of molecular sciences · 2026Review
- A microparticle delivery system for extended release of all-trans retinoic acid and its impact on macrophage insulin-like growth factor 1 release and myotube formation.International journal of pharmaceutics · 2024Article
- A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice.Journal of visualized experiments : JoVE · 2024Article
- Actions and interactions of IGF-I and MMPs during muscle regeneration.Seminars in cell & developmental biology · 2021Review
- Deletion of muscleJournal of applied physiology (Bethesda, Md. : 1985) · 2021Article
- The impact of hindlimb disuse on sepsis-induced myopathy in mice.Physiological reports · 2021Article
- Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics.Endocrinology and metabolism (Seoul, Korea) · 2021Review
- Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors.International journal of molecular sciences · 2020Review
- Review
- Matrix Metalloproteinase 13 from Satellite Cells is Required for Efficient Muscle Growth and Regeneration.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2020Article
- Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy.American journal of physiology. Endocrinology and metabolism · 2019Article
- Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin.Muscle & nerve · 2019Article
- Article
- miR-29b contributes to multiple types of muscle atrophy.Nature communications · 2017Article
- RNA-seq and metabolomic analyses of Akt1-mediated muscle growth reveals regulation of regenerative pathways and changes in the muscle secretome.BMC genomics · 2017Article
- Optimizing IGF-I for skeletal muscle therapeutics.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2014Review
- Viral expression of insulin-like growth factor I E-peptides increases skeletal muscle mass but at the expense of strength.American journal of physiology. Endocrinology and metabolism · 2014Article
- SMASH - semi-automatic muscle analysis using segmentation of histology: a MATLAB application.Skeletal muscle · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Prolonged disuse of skeletal muscle results in atrophy, and once physical activity is resumed, there is increased susceptibility to injury. Insulin-like growth factor-I (IGF-I) is considered a potential therapeutic target to attenuate atrophy during unloading and to enhance rehabilitation upon reloading of skeletal muscles, due to its multipronged actions on satellite cell proliferation, differentiation, and survival, as well as its actions on muscle fibers to boost protein synthesis and inhibit protein degradation. However, the form of IGF-I delivered may alter the success of treatment. Using the hindlimb suspension model of disuse atrophy, we compared the efficacy of two IGF-I forms in protection against atrophy and enhancement of recovery: mature IGF-I (IGF-IS) lacking the COOH-terminal extension, called the E-peptide, and IGF-IA, which is the predominant form retaining the E-peptide. Self-complementary adeno-associated virus harboring the murine Igf1 cDNA constructs were delivered to hindlimbs of adult female C57BL6 mice 3 days prior to hindlimb suspension. Hindlimb muscles were unloaded for 7 days and then reloaded for 3, 7, and 14 days. Loss of muscle mass following suspension was not prevented by either IGF-I construct. However, IGF-IS expression maintained soleus muscle force production. Further, IGF-IS treatment caused rapid recovery of muscle fiber morphology during reloading and maintained muscle strength. Analysis of gene expression revealed that IGF-IS expression accelerated the downregulation of atrophy-related genes compared with untreated or IGF-IA-treated samples. We conclude that mature-IGF-I may be a better option than pro-IGF-IA to promote skeletal muscle recovery following disuse atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.